What is clock.bio?
clock.bio operates at the intersection of advanced cellular biology and therapeutic development. By decoding the natural rejuvenation programs inherent in human cells, the company aims to engineer novel treatments that address the root causes of age-related pathologies. Unlike traditional pharmaceutical approaches that focus on symptom management, clock.bio is building a platform designed to restore cellular function. This scientific rigor is supported by a unique partnership model that integrates academic research with operational expertise, ensuring that their breakthroughs in regenerative medicine remain both ethically grounded and scalable for global accessibility.
How much funding has clock.bio raised?
clock.bio has raised a total of $5.3M across 1 funding round:
Angel/Seed
$5.3M
Angel/Seed (2024): $5.3M with participation from Onsight Ventures, LocalGlobe, and BlueYard Capital
Key Investors in clock.bio
Onsight Ventures
Onsight Ventures is a deep tech investment fund based in Innsbruck that focuses on empowering European founders to become global leaders in technology-driven sectors, with a specific interest in gene therapy and synthetic biology.
BlueYard Capital
BlueYard Capital is a venture capital firm that invests in innovative technologies across various sectors, including computation, engineering, and biology, supporting founders who are building solutions to significant global challenges.
LocalGlobe
LocalGlobe is a prominent venture capital firm known for its early-stage support of transformative technology companies, providing both capital and strategic guidance to high-growth startups.
What's next for clock.bio?
With this latest infusion of capital, clock.bio is expected to transition from its foundational research phase into more intensive clinical development and validation. The strategic roadmap likely involves expanding its laboratory infrastructure and deepening its intellectual property portfolio regarding cellular reprogramming. As the company scales, it will focus on refining its therapeutic candidates to meet regulatory standards, while simultaneously exploring partnerships that can facilitate the transition from bench-side discovery to patient-facing applications. The focus remains on maintaining a competitive edge in the rapidly evolving longevity market, where the ability to translate complex biological data into actionable medical interventions will be the primary driver of long-term value creation.
See full clock.bio company page
